ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2020
The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Trial
- Prescribing Practices, Polypharmacy, and Drug Interaction Risks in Anticoagulant Therapy: Insights from a Secondary Care Hospital.Journal of clinical medicine · 2026Article
- Patient Activation Among Individuals with Chronic Illness: A Cross-Sectional Study from Jordan.Healthcare (Basel, Switzerland) · 2026Article
- Potential drug-drug interactions in hospitalized patients with acute coronary syndrome at a tertiary care hospital in upper Egypt.Frontiers in pharmacology · 2026Article
- Prevalence, predictors, and clinical relevance of drug-drug interactions in outpatient prescribing: A national cross-sectional study.PloS one · 2026Article
- Evaluation of potential drug-drug interactions and its determinants among outpatient prescriptions in six community chain pharmacies in Asmara, Eritrea: a cross-sectional study.Scientific reports · 2025Article
- The Prevalence of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes in Jordan: The PACT-MEA Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Evaluation of drug interactions in outpatients taking antipsychotic medications.Frontiers in pharmacology · 2025Article
- Prescription Patterns of Inducers and Inhibitors of Cytochrome P450 and Their Potential Drug Interactions in the Real World: A Cross-Sectional Study.Drugs - real world outcomes · 2024Article
- Article
- A Review of Risk Factors for Polypharmacy: Age, Level of Education, and Physician's Attitude.Cureus · 2024Review
- Are there any potential drug-drug interactions with oral inhaler medications?: A retrospective study.Exploratory research in clinical and social pharmacy · 2024Article
- Prevalence and factors associated with potential drug-drug interactions in prescriptions presented at private pharmacies in Mbarara city, southwestern Uganda.BMC pharmacology & toxicology · 2024Article
- Current Landscape and Future Directions of Deprescribing and Polypharmacy Practices in Jordan.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Review
- Article
- Risk Factors for Potential Drug-Drug Interactions in Outpatients with Dyslipidemia.Iranian journal of public health · 2023Article
- Drug-Drug Interactions and the Risk of Emergency Hospitalizations: A Nationwide Population-Based Study.Drug safety · 2023Article
- Potential drug-drug interactions in outpatients with depression of a psychiatry department.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Assessment of risk factors associated with potential drug-drug interactions among patients suffering from chronic disorders.PloS one · 2023Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the prevalence of potential drug-drug interactions (pDDIs) among polypharmacy patients in Jordan using Lexicomp®. Additionally, this study aims to categorize and rate the identified pDDIs according to interaction risk, severity, and reliability.
methodsA descriptive cross-sectional study was conducted at six different hospitals representing different public health sectors in Jordan (ministry of health, royal medical services, and university-affiliated hospitals). Polypharmacy patients from outpatient clinics (e.g., cardiology,& and internal medicine) were identified, recruited, and interviewed by clinical pharmacists. pDDIs were assessed using the Lexicomp® mobile application and classified according to interaction risk rating, severity, and reliability rating. Furthermore, the prevalence of pDDIs across chronic medical conditions was assessed. P-value <0.05 was considered as significant.
resultsA total of 801 patients with polypharmacy were identified. The average number of drugs per patient was 6.6 ± 1.96, with an average of 4.2 ± 3.0 pDDIs per patient. Potential drug-drug interactions were detected in 769 patients (96%), with a total of 3359 interactions. Blood pressure lowering agents were involved in 39.9% of the pDDIs. Cardiovascular system drugs contributed to the largest share of pDDIs (46.6%). While diuretics had the major share of interactions among cardiovascular system drugs (16.2%), drugs used in diabetes had the highest share across all groups (17.1%). The majority of pDDIs were of "C" risk rating with a moderate interaction severity, whilst 1.6% of pDDIs could have been avoided in the first place as the concurrent administration of these agents is contraindicated (i.e., risk rating X). Patients with cardiovascular diseases, diabetes, chronic obstructive pulmonary disease, gout, and chronic kidney disease were associated with the highest number of potential drug-drug interactions.
conclusionOur study showed that 96% of polypharmacy patients at outpatient clinics have at least one pDDI. Almost half of the detected interactions involved cardiovascular medications. The majority of these pDDIs had moderate severity, with no more than 10% of the interactions requiring therapy modification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.